Studies indicate that daily medication compliance is only 72%, which negatively impacts treatment success.
More than 40% of prescribed buprenorphine is diverted.
Treatment drop-out typically happens around Day 100 of treatment: far too early.
Public safety concerns persist, as buprenorphine was the most common active ingredient in emergency hospitalizations of children five years old or younger from 2007-2011.
Patient compliance - taking the right dose of prescribed buprenorphine at the right time - is associated with better success rates in addiction treatment.
Conversely, poor compliance correlates with heightened risk of illicit opioid use.
Sharing and selling of buprenorphine is commonly reported. So the DEA compels prescribers to track patients carefully and compile detailed records.
All of this contributes to a need for safe, effective prescription monitoring, so treatment can be available to more people.